Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population

HIV / AIDS

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals

Clin Infect Dis.

Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT, Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team .

doi: 10.1093/cid/ciy913.

HIV / AIDS

Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons

AIDS.

Mocroft A, Ryom L, Oprea C, Li Q, Rauch A, Boesecke C, Uzdaviniene V, Sedlacek D, Llibre JM, Lacombe K, Nielsen LN, Florence E, Aho I, Chkhartishvili N, Szlavik J, Dragovic G, Leen C, Sambatakou H, Staub T, Laguno M, Elinav H, Tomažič J, Peters L, EuroSIDA study group.

doi: 10.1097/QAD.0000000000002570.

Viral Infections, Non-HIV

Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review

J Viral Hepat.

Goossens N, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D'Ambrosio R, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Müllhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-Brandt , Negro F

doi: 10.1111/jvh.12891.

Viral Infections, Non-HIV

Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland

Swiss Med Wkly.

Bachofner J, Valli PV, Bergamin I, Kröger A, Künzler P, Baserga A, Braun DL, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Müllhaupt B, Terziroli Beretta-Piccoli B, Mertens J, The Swiss Hepatitis C Cohort Study.

doi: 10.4414/smw.2018.14560.

Viral Infections, Non-HIV

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Lancet Infect Dis.

Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ

doi: 10.1016/

Viral Infections, Non-HIV

Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1

Lancet Gastroenterol Hepatol.

Bourlière M, Gordon SC, Schiff ER, Tran TT, Ravendhran N, Landis CS, Hyland RH, Stamm LM, Zhang J, Dvory-Sobol H, Subramanian GM, Brainard DM, McHutchison JG, Serfaty L, Thompson AJ, Sepe TE, Curry MP, Reddy KR, Manns MP

doi: 10.1016/

Viral Infections, Non-HIV

Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial

Ann Intern Med.

Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S; and the ASCEND Providers

doi: 10.7326/M17-0118.

HIV / AIDSViral Infections, Non-HIV

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study

Lancet Infect Dis.

Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL

doi: 10.1016/

Viral Infections, Non-HIV

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030

Swiss Med Wkly.

Bruggmann P, Blach S, Deltenre P, Fehr J, Kouyos R, Lavanchy D, Müllhaupt B, Rauch A, Razavi H, Schmid P, Semela D, Stoeckle M, Negro F

doi: 10.4414/smw.2017.14543.

Related content

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals

Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons

Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review

Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1

Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030